Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease

DUBLIN, Ireland, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
October 23, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual Meeting

-- Initial data from investigator-initiated TRIPLE study to be presented on Nov. 6 -- -- Horizon Pharma plc to host an investor call on Nov. 9 following the ACR/AHRP Annual Meeting -- DUBLIN,...
October 17, 2017 08:30 ET | Source: Horizon Pharma plc

Horizon Pharma plc Named One of the Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the Second Year in a Row

DUBLIN, Ireland, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
October 10, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc to Host Third-Quarter 2017 Conference Call and Webcast on Nov. 6, 2017

DUBLIN, Ireland, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
October 02, 2017 16:30 ET | Source: Horizon Pharma plc

Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DUBLIN, IRELAND, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
September 13, 2017 16:05 ET | Source: Horizon Pharma plc

Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DUBLIN, Ireland, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
September 11, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer

DUBLIN, Ireland, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring...
September 05, 2017 16:05 ET | Source: Horizon Pharma plc

Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DUBLIN, Ireland, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
August 24, 2017 08:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference

DUBLIN, Ireland, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
August 07, 2017 07:00 ET | Source: Horizon Pharma plc

Horizon Pharma plc Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance

-- Second-Quarter 2017 Net Sales of $289.5 Million; Up 12 Percent, Above Expectations ---- Second-Quarter 2017 Net Loss of $209.5 Million; Adjusted EBITDA of $127.0 Million, Above Expectations ----...